European Heart Journal Advance Access originally published online on January 26, 2005
European Heart Journal 2005 26(5):440-446; doi:10.1093/eurheartj/ehi104
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome
An ENTIRE-TIMI 23 substudy
The TIMI Study Group and Cardiovascular Division, Department of Medicine, Brigham & Women's Hospital/Harvard Medical School, Boston, MA, USA
Received 15 July 2004; revised 14 November 2004; accepted 25 November 2004; online publish-ahead-of-print 26 January 2005.
* Corresponding author: TIMI Study Group, 350 Longwood Avenue, First Floor, Boston, MA 02115, USA. Tel: +1 617 525 6865; fax: +1 617 734 7329. E-mail address: kkray{at}partners.org
See page 421 for the editorial comment on this article (doi:10.1093/eurheartj/ehi125)
Aims Prior studies suggest that acute coronary syndromes (ACSs) are associated with endothelial activation and that this is of prognostic significance. We hypothesized that endothelial activation, as measured by a rise in von Willebrand Factor (
vWF), was influenced by the thrombolysis in myocardial infarction flow grade (TFG), the corrected TIMI frame count (CTFC) and the choice of anticoagulant therapy after fibrinolysis in ST elevation myocardial infarction (STEMI).
Methods and results Data were drawn from the enoxaparin and tenecteplase tissue plasminogen activator (TNK-tpa) with or without GPIIb/IIIa inhibitor as the reperfusion strategy in the STEMI trial (ENTIRE-TIMI 23). Three hundred and fourteen patients had serial measurements of vWF (baseline and 48–72 h) and angiographic data available. TFG<3 (P=0.0042) or CTFC
40 at 60 min (P=0.0035) were associated with a higher vWF. vWF 75th percentile was associated with a higher incidence of death or myocardial infarction (MI) at 30 days, compared with <75th percentile (11.2 vs. 4.1%, P=0.027). Enoxaparin independently reduced the vWF (P=0.019) and also the composite of death or MI (OR 0.33, 95% CI 0.12–0.91, P=0.03) compared with unfractionated heparin.
Conclusion In STEMI treated by fibrinolysis, coronary flow at 60 min and choice of adjunctive anticoagulant appear to be independent determinants of vWF. Enoxaparin is independently associated with a reduction in vWF and a reduction in death or MI. The clinical benefits of enoxaparin as an adjunctive treatment in STEMI may be mediated in part by a reduction in vWF release.
Key Words: vWF • TIMI flow grade • Corrected TIMI frame count • ST elevation myocardial infarction • Endothelial activation
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in EHJ:
- The investigation of biomarkers in cardiovascular disease: time for a coordinated, international effort
- Richard C. Becker
EHJ 2005 26: 421-422.[Extract] [FREE Full Text]
This article has been cited by other articles:
|
|
 |
|
  A. O. Spiel, J. C. Gilbert, and B. Jilma Von Willebrand Factor in Cardiovascular Disease: Focus on Acute Coronary Syndromes Circulation, March 18, 2008; 117(11): 1449 - 1459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Gilbert, T. DeFeo-Fraulini, R. M. Hutabarat, C. J. Horvath, P. G. Merlino, H. N. Marsh, J. M. Healy, S. BouFakhreddine, T. V. Holohan, and R. G. Schaub First-in-Human Evaluation of Anti von Willebrand Factor Therapeutic Aptamer ARC1779 in Healthy Volunteers Circulation, December 4, 2007; 116(23): 2678 - 2686. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Montalescot and on behalf of the OPERA investigators STEMI and NSTEMI are two distinct pathophysiological entities: reply Eur. Heart J., November 1, 2007; 28(21): 2685 - 2686. [Full Text] [PDF]
|
|
|
|
|
|
C. J. Boos, S. K. Soor, D. Kang, and G. Y.H. Lip Relationship between circulating endothelial cells and the predicted risk of cardiovascular events in acute coronary syndromes Eur. Heart J., May 1, 2007; 28(9): 1092 - 1101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Anwaruddin, A. T. Askari, and E. J. Topol Redefining Risk in Acute Coronary Syndromes Using Molecular Medicine J. Am. Coll. Cardiol., January 23, 2007; 49(3): 279 - 289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Tanne, R. F. Macko, Y. Lin, B. C. Tilley, S. R. Levine, and for the NINDS rtPA Stroke Study Group Hemostatic Activation and Outcome After Recombinant Tissue Plasminogen Activator Therapy for Acute Ischemic Stroke Stroke, July 1, 2006; 37(7): 1798 - 1804. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Armstrong, D. A. Morrow, and M. S. Sabatine Inflammatory Biomarkers in Acute Coronary Syndromes: Part II: Acute-Phase Reactants and Biomarkers of Endothelial Cell Activation Circulation, February 21, 2006; 113(7): e152 - e155. [Full Text] [PDF]
|
|
|
|
|
|
M. S. Sabatine, D. A. Morrow, G. Montalescot, M. Dellborg, J. L. Leiva-Pons, M. Keltai, S. A. Murphy, C. H. McCabe, C. M. Gibson, C. P. Cannon, et al. Angiographic and Clinical Outcomes in Patients Receiving Low-Molecular-Weight Heparin Versus Unfractionated Heparin in ST-Elevation Myocardial Infarction Treated With Fibrinolytics in the CLARITY-TIMI 28 Trial Circulation, December 20, 2005; 112(25): 3846 - 3854. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. K. Ray and C. P. Cannon The Potential Relevance of the Multiple Lipid-Independent (Pleiotropic) Effects of Statins in the Management of Acute Coronary Syndromes J. Am. Coll. Cardiol., October 18, 2005; 46(8): 1425 - 1433. [Abstract] [Full Text] [PDF]
|
|